Systemic sclerosis & Raynaud's
Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis
Study context
- Population
- Patients with systemic sclerosis (SSc); autoantibody profiling at SSc diagnosis, prior to any specific treatment
- Participants
- 290 patients
- Outcome
- Prevalence of cancer (prevalent and incident malignancy)
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
Overall prevalence of cancer
Overall prevalence of cancer
20%
Observational data: associations, not effects.
Further findings
Cancer-associated scleroderma (cancer within 3 years of SSc onset)
- Proportion of cases being cancer-associated scleroderma
- 8%
- Cancer and cancer-associated scleroderma more frequent in elderly patients and with positive anti-Ro52 or anti-U3-RNP
- Cancer-associated scleroderma significantly more prevalent in patients negative for both ACA and TOPO1, especially in diffuse SSc
Immunosuppressants and cancer
- Immunosuppressants not significantly associated with cancer
Breast cancer
- Significantly higher risk in patients triple negative for ACA, TOPO1 and anti-RNA polymerase III antibodies
Original publication
Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis. RMD Open. Published 20 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →